241 related articles for article (PubMed ID: 20297858)
1. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
Carter NJ; Keating GM
CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
3. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
Coluzzi F; Mattia C
Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
[TBL] [Abstract][Full Text] [Related]
4. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
[TBL] [Abstract][Full Text] [Related]
5. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
Sabatowski R; Giesecke T
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
[TBL] [Abstract][Full Text] [Related]
8. Hydromorphone-OROS formulation.
Goforth HW
Expert Opin Pharmacother; 2010 May; 11(7):1207-14. PubMed ID: 20402557
[TBL] [Abstract][Full Text] [Related]
9. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
10. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
[TBL] [Abstract][Full Text] [Related]
11. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
Hauber AB; Fleischmann J; Lothgren M; Wilson M; Lam A; Dubois D; Sabatowski R
J Opioid Manag; 2011; 7(4):287-96. PubMed ID: 21957828
[TBL] [Abstract][Full Text] [Related]
13. Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.
Park CK; Kang HW; Oh IJ; Kim YC; Kim YK; Na KJ; Ahn SJ; Kim TO; Choi YJ; Song GA; Lee MK
J Korean Med Sci; 2016 Dec; 31(12):1914-1921. PubMed ID: 27822929
[TBL] [Abstract][Full Text] [Related]
14. The role of OROS hydromorphone in the management of cancer pain.
Gardner-Nix J; Mercadante S
Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
[TBL] [Abstract][Full Text] [Related]
15. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
J Int Med Res; 2008; 36(2):343-52. PubMed ID: 18380946
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
[TBL] [Abstract][Full Text] [Related]
17. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
Rauck R; Rapoport R; Thipphawong J
Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
[TBL] [Abstract][Full Text] [Related]
18. Use of hydromorphone, with particular reference to the OROS formulation, in the elderly.
Lussier D; Richarz U; Finco G
Drugs Aging; 2010 Apr; 27(4):327-35. PubMed ID: 20361803
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
20. The metamorphosis of hydromorphone.
Reisfield GM; Wilson GR
J Opioid Manag; 2005; 1(3):139-45. PubMed ID: 17315417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
